首页/数据集/Additional file 6 of Targeting E2F8 sensitizes gemcitabine-resistant gallbladder cancer to PARP inhibitors by disrupting RRM2-driven DNA repair

Additional file 6 of Targeting E2F8 sensitizes gemcitabine-resistant gallbladder cancer to PARP inhibitors by disrupting RRM2-driven DNA repair

Figshare2025-12-14 更新2026-04-28 收录

胆囊癌耐药机制

PARP1抑制剂治疗

数据链接：

https://figshare.com/articles/dataset/Additional_file_6_of_Targeting_E2F8_sensitizes_gemcitabine-resistant_gallbladder_cancer_to_PARP_inhibitors_by_disrupting_RRM2-driven_DNA_repair/31103038 数据链接链接失效反馈

官方服务：

资源简介：

Supplementary Material 6.

应用场景：

创建时间：

2025-12-14

胰腺癌治疗

PARP1抑制剂治疗

Background Pancreatic cancer remains a lethal disease with limited therapeutic options. The field of targeted therapies is still growing. Treatment with PARP inhibitors has been successfully described

DataCite Commons2025-06-01 更新80

Discovery of Ruthenium(II) Metallocompound and Olaparib Synergy for Cancer Combination Therapy

癌症药物协同筛选

PARP1抑制剂治疗

Synergistic drug combinations can extend the use of poly(ADP-ribose) polymerase inhibitors (PARPi) such as Olaparib to BRCA-proficient tumors and overcome acquired or de novo drug resistance. To ident

Figshare2023-05-15 更新40

Genome-wide occupation of AR, FOXA1, and H3K27AC in LNCaP cells treated with selective PARP2 inhibitor UPF-1069. Genome-wide occupation of AR, FOXA1, and H3K27AC in LNCaP cells treated with selective PARP2 inhibitor UPF-1069

前列腺癌分子机制

PARP1抑制剂治疗

Androgen receptor (AR) signaling is a key driver of prostate cancer (PCa) growth and progression. Understanding the factors influencing AR-mediated transcription provides new opportunities for therape

NIAID Data Ecosystem20

Table_2_Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells.xlsx

三阴性乳腺癌耐药性

PARP1抑制剂治疗

Poly (ADP-ribose) polymerase inhibitor (PARPi) resistance is a new challenge for antitumor therapy. The purpose of this study was to investigate the reversal effects of chidamide on fluzoparib resista

NIAID Data Ecosystem50

Supplementary Table S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

前列腺癌分子机制

PARP1抑制剂治疗

Supplementary Table S10. Quantification of each protein-specific band normalized to vinculin (Dox-inducible RM-1-BM–derived models, Fig. 4D, lower panel).

NIAID Data Ecosystem20

Additional file 6 of Targeting E2F8 sensitizes gemcitabine-resistant gallbladder cancer to PARP inhibitors by disrupting RRM2-driven DNA repair

资源简介：

相关数据集